Inhibition of SHP2 with JAB-3312 improves anti-tumor response in models, suggesting synergy with PD-1 blockade.
Supplementary Figure S9. The anti-tumor activity of JAB-3312 was abrogated by CD8+ T cell depletion. A-B. Tumor growth change (A) and body weight change (B) of MC38 syngeneic model during the treatment. Mean ± SEM was shown.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: